The discovery and application of gene fusions in prostate cancer

BJU International

Volumn 102, Issue 3, 2008, Pages 276-282

  Morris, David S ^a   Tomlins, Scott A ^a   Montie, James E ^a   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Gene fusion; Prostate cancer

Indexed keywords

ANDROGEN; PROTEINASE; TRANSCRIPTION FACTOR;

AVIAN ERYTHROBLASTOSIS ONCOVIRUS; CANCER SCREENING; GENE FUSION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TRANSLOCATION; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

GENE EXPRESSION; GENE FUSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 47649121363     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07665.x     Document Type: Review

References (45)

1. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007 7 : 233 45
2. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994 372 : 143 9
3. Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 2001 1 : 245 50
4. Harrison CJ, Griffiths M, Moorman F et al. A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. Cancer Genet Cytogenet 2007 173 : 17 22
5. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 105 : 2640 53
6. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 310 : 644 8
7. Ross ME, Zhou X, Song G et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003 102 : 2951 9
8. Valk PJ, Verhaak RG, Beijen MA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004 350 : 1617 28
9. Vasselli JR, Shih JH, Iyengar SR et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 2003 100 : 6958 63
10. Lapointe J, Li C, Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004 101 : 811 6
11. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003 349 : 2483 94
12. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001 412 : 822 6
13. Welsh JB, Sapinoso LM, Su AI et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001 61 : 5974 8
14. Zhan F, Hardin J, Kordsmeier B et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002 99 : 1745 57
15. Huang E, Cheng SH, Dressman H et al. Gene expression predictors of breast cancer outcomes. Lancet 2003 361 : 1590 6
16. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004 113 : 913 23
17. Yu YP, Landsittel D, Jing L et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004 22 : 2790 9
18. Hsu T, Trojanowska M, Watson DK. Ets proteins in biological control and cancer. J Cell Biochem 2004 91 : 896 903
19. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003 303 : 11 34
20. Mehra R, Tomlins SA, Shen R et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007 20 : 538 44
21. Mosquera JM, Perner S, Demichelis F et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 2007 212 : 91 101
22. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007 17 : 1033 6
23. Lapointe J, Kim YH, Miller M et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007 20 : 467 73
24. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006 66 : 8347 51
25. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007 26 : 4596 9
26. Cerveira N, Ribeiro FR, Peixoto A et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006 8 : 826 32
27. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006 66 : 10658 63
28. Iljin K, Wolf M, Edgren H et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006 66 : 10242 6
29. Nam RK, Sugar L, Wang Z et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007 6 : 40 5
30. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006 66 : 8337 41
31. Rajput AB, Miller MA, De Luca A et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007 60 : 1238 43
32. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006 45 : 717 9
33. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007 20 : 921 8
34. Yoshimoto M, Joshua AM, Chilton-Macneill S et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006 8 : 465 9
35. Tomlins SA, Mehra R, Rhodes DR et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006 66 : 3396 400
36. Afar DE, Vivanco I, Hubert RS et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res 2001 61 : 1686 92
37. Lin B, Ferguson C, White JT et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999 59 : 4180 4
38. Mertz KD, Setlur SR, Dhanasekaran SM et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007 9 : 200 6
39. Perner S, Mosquera JM, Demichelis F et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007 31 : 882 8
40. Tomlins SA, Laxman B, Dhanasekaran SM et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007 448 : 595 9
41. Klezovitch O, Risk M, Coleman I et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008 105 : 2105 10
42. Tomlins SA, Laxman B, Varambally S et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008 10 : 177 88
43. Laxman B, Tomlins SA, Mehra R et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006 8 : 885 8
44. Laxman B, Morris DS, Yu J et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008 68 : 645 9
45. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007 13 : 5103 8